| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02587962 | Solid Tumors | Drug: Birinapant|Drug: Pembrolizumab | TetraLogic Pharmaceuticals|Merck Sharp & Dohme Corp. | Phase 1|Phase 2 | 2017-02-01 | 2016-10-18 |
| NCT02147873 | Myelodysplastic Syndrome (MDS)|Chronic Myelomonocytic Leukemia (CMML) | Drug: birinapant|Drug: Azacitidine|Drug: Placebo | TetraLogic Pharmaceuticals | Phase 2 | 2014-06-01 | 2016-10-18 |
| NCT01940172 | Relapsed Epithelial Ovarian Cancer|Relapsed Primary Peritoneal Cancer|Relapsed Fallopian Tube Cancer | Drug: Birinapant|Drug: Conatumumab | TetraLogic Pharmaceuticals | Phase 1 | 2013-11-01 | 2016-01-13 |
| NCT01828346 | Myelodysplastic Syndrome | Drug: Birinapant|Drug: 5-Azacitidine | TetraLogic Pharmaceuticals | Phase 1|Phase 2 | 2013-06-01 | 2016-04-19 |
| NCT01188499 | Cancer | Drug: Birinapant | TetraLogic Pharmaceuticals | Phase 1|Phase 2 | 2010-10-01 | 2016-04-21 |
| NCT02288208 | Hepatitis B | Drug: Antiviral Therapy (tenofovir or entecavir)|Drug: Birinapant|Drug: Placebo (for birinapant) | TetraLogic Pharmaceuticals | Phase 1 | 2014-11-01 | 2016-02-04 |
| NCT02756130 | Advanced Newly Diagnosed or Recurrent High Grade Serous Carcinomas (HGSC) | Drug: Birinapant|Drug: Paclitaxel|Drug: Carboplatin | Jonsson Comprehensive Cancer Center|TetraLogic Pharmaceuticals | Phase 2 | 2017-01-01 | 2017-01-20 |
| NCT01681368 | Epithelial Ovarian Cancer|Peritoneal Neoplasms|Fallopian Tube Neoplasms | Drug: Birinapant (TL32711) | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) | Phase 2 | 2012-08-01 | 2015-10-14 |
| NCT00993239 | Cancer | Drug: Birinapant (TL32711) | TetraLogic Pharmaceuticals | Phase 1 | 2009-11-01 | 2016-03-01 |
| NCT01573780 | Unspecified Adult Solid Tumor, Protocol Specific | Drug: Smac mimetic TL32711|Drug: gemcitabine hydrochloride|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: biopsy | Roswell Park Cancer Institute|National Cancer Institute (NCI)|TetraLogic Pharmaceuticals | Phase 1 | 2012-04-01 | 2014-01-14 |
| NCT01766622 | Ovarian Neoplasms|Ovarian Cancer|Fallopian Tube Neoplasms|Fallopian Tube Cancer | Drug: [18F]-CP18|Procedure: PET/ CT | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI) | Phase 2 | 2012-11-30 | 2017-01-24 |
| NCT01486784 | Acute Myelogenous Leukemia | Drug: TL32711 | Abramson Cancer Center of the University of Pennsylvania | Phase 1|Phase 2 | 2011-11-01 | 2017-01-24 |
